The Asia Pacific Bispecific Antibodies Market would witness market growth of 42.8% CAGR during the forecast period (2023-2030).
Complex and varied mechanisms underlying inflammatory and autoimmune illnesses include cytokine imbalances, dysregulated immune responses, and aberrant cell signaling pathways. Traditional treatments frequently concentrate on a single molecular route or target, which reduces their effectiveness. Multiple targets can be engaged by bispecific antibodies like tibulizumab, ozoralizumab, and others. These give a more thorough approach to modifying these intricate disease systems, which may result in better outcomes.
Additionally, as more bispecific antibodies receive regulatory approval, businesses are more interested and confident in investing in R&D. The FDA, for instance, approved Teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), which is the first BsAb B-cell maturation antigen, in October 2022 for adult patients with relapsed or refractory multiple myeloma. In order to take advantage of complementary skills and technology to generate bispecific antibodies, businesses are also actively collaborating and forming partnerships. Through these partnerships, research & development activities are increased, further accelerating market expansion.
The latest developments in applied science are being utilized by Chinese pharmaceutical businesses as they develop their unique technologies. Additionally, by combining a non-competing pair of human neutralizing antibodies, namely H4 and B38, to target two antigens, the researchers from Capital Medical University and the Chinese Academy of Sciences created the bispecific human mAbs against SARS-CoV-2. This prevented the virus from attaching to its receptor. The study, just published in Nature Immunology, found that the double-kill antibody, or bsAb15, has a higher neutralizing effectiveness than its parental antibodies and more neutralizing efficacy against the Delta variation. Such developments have successfully aided in the development of the regional market.
The China market dominated the Asia Pacific Bispecific Antibodies Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,437 million by 2030. The Japan market is exhibiting a CAGR of 41.9% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 43.7% during (2023 - 2030).
Based on Indication, the market is segmented into Cancer, Inflammatory & Autoimmune Disorder and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Bispecific Antibodies Market is Projected to reach USD 80.2 Billion by 2030, at a CAGR of 40.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Akeso, Inc., Johnson & Johnson (Janssen Global Services, LLC), Taisho Pharmaceuticals Holding Co., Ltd., Immunocore Holdings plc, GlaxoSmithKline PLC (GSK), Novartis AG, and Allergan PLC (AbbVie, Inc.).
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Cancer
- Inflammatory & Autoimmune Disorder
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Amgen, Inc.
- F.Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Akeso, Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Taisho Pharmaceuticals Holding Co., Ltd.
- Immunocore Holdings plc
- GlaxoSmithKline PLC (GSK)
- Novartis AG
- Allergan PLC (AbbVie, Inc.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Bispecific Antibodies Market, by Indication
1.4.2 Asia Pacific Bispecific Antibodies Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Trials and Approvals
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
Chapter 4. Asia Pacific Bispecific Antibodies Market by Indication
4.1 Asia Pacific Cancer Market by Country
4.2 Asia Pacific Inflammatory & Autoimmune Disorder Market by Country
4.3 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Bispecific Antibodies Market by Country
5.1 China Bispecific Antibodies Market
5.1.1 China Bispecific Antibodies Market by Indication
5.2 Japan Bispecific Antibodies Market
5.2.1 Japan Bispecific Antibodies Market by Indication
5.3 India Bispecific Antibodies Market
5.3.1 India Bispecific Antibodies Market by Indication
5.4 South Korea Bispecific Antibodies Market
5.4.1 South Korea Bispecific Antibodies Market by Indication
5.5 Singapore Bispecific Antibodies Market
5.5.1 Singapore Bispecific Antibodies Market by Indication
5.6 Malaysia Bispecific Antibodies Market
5.6.1 Malaysia Bispecific Antibodies Market by Indication
5.7 Rest of Asia Pacific Bispecific Antibodies Market
5.7.1 Rest of Asia Pacific Bispecific Antibodies Market by Indication
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Acquisition and Mergers:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Trials and Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional & Segmental Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 Akeso, Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 Johnson & Johnson (Janssen Global Services, LLC)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental &Regional Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Partnerships, Collaborations, and Agreements:
6.5.5.2 Acquisition and Mergers:
6.6 Taisho Pharmaceuticals Holding Co., Ltd.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.7 Immunocore Holdings plc
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.7.4 Recent strategies and developments:
6.7.4.1 Partnerships, Collaborations, and Agreements:
6.8 GlaxoSmithKline PLC (GSK)
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.9 Novartis AG
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.10. Allergan PLC (AbbVie, Inc.)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
TABLE 1 Asia Pacific Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Bispecific Antibodies Market
TABLE 4 Trials and Approvals – Bispecific Antibodies Market
TABLE 5 Acquisition and Mergers– Bispecific Antibodies Market
TABLE 6 Asia Pacific Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 7 Asia Pacific Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 8 Asia Pacific Cancer Market by Country, 2019 - 2022, USD Million
TABLE 9 Asia Pacific Cancer Market by Country, 2023 - 2030, USD Million
TABLE 10 Asia Pacific Inflammatory & Autoimmune Disorder Market by Country, 2019 - 2022, USD Million
TABLE 11 Asia Pacific Inflammatory & Autoimmune Disorder Market by Country, 2023 - 2030, USD Million
TABLE 12 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 13 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
TABLE 14 Asia Pacific Bispecific Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 15 Asia Pacific Bispecific Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 16 China Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 17 China Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 18 China Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 19 China Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 20 Japan Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 21 Japan Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 22 Japan Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 23 Japan Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 24 India Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 25 India Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 26 India Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 27 India Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 28 South Korea Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 29 South Korea Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 30 South Korea Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 31 South Korea Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 32 Singapore Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 33 Singapore Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 34 Singapore Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 35 Singapore Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 36 Malaysia Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 37 Malaysia Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 38 Malaysia Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 39 Malaysia Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 40 Rest of Asia Pacific Bispecific Antibodies Market, 2019 - 2022, USD Million
TABLE 41 Rest of Asia Pacific Bispecific Antibodies Market, 2023 - 2030, USD Million
TABLE 42 Rest of Asia Pacific Bispecific Antibodies Market by Indication, 2019 - 2022, USD Million
TABLE 43 Rest of Asia Pacific Bispecific Antibodies Market by Indication, 2023 - 2030, USD Million
TABLE 44 Key Information – Amgen, Inc.
TABLE 45 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 46 Key Information – Pfizer, Inc.
TABLE 47 Key Information – Akeso, Inc.
TABLE 48 Key information –Johnson & Johnson
TABLE 49 key Information – Taisho Pharmaceuticals Holding Co., Ltd.
TABLE 50 Key Information – Immunocore Holdings plc
TABLE 51 Key Information – GlaxoSmithKline PLC
TABLE 52 Key Information – Novartis AG
TABLE 53 Key Information – Allergan PLC
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Jun – 2022, Dec) Leading Players
FIG 5 Asia Pacific Bispecific Antibodies Market share by Indication, 2022
FIG 6 Asia Pacific Bispecific Antibodies Market share by Indication, 2030
FIG 7 Asia Pacific Bispecific Antibodies Market by Indication, 2019 - 2030, USD Million
FIG 8 Asia Pacific Bispecific Antibodies Market share by Country, 2022
FIG 9 Asia Pacific Bispecific Antibodies Market share by Country, 2030
FIG 10 Asia Pacific Bispecific Antibodies Market share by Country, 2019 - 2030, USD Million
FIG 11 Recent strategies and developments: Johnson & Johnson